THEMIS-PCI Benefit vs Bleeding Algorithm

Clinical calculation support · Verify results before clinical use

Patient bleeding-risk inputs

Enter baseline findings to calculate CRUSADE.

CRUSADE score

About the algorithm

THEMIS-PCI was a prespecified subgroup analysis in patients with type 2 diabetes, stable coronary artery disease, and previous PCI. Median follow-up was 3.3 years. The primary efficacy outcome was cardiovascular death, myocardial infarction, or stroke.

OutcomeTicagrelor + aspirinAspirin alone
CV death, MI, or stroke7.3%8.6%
TIMI major bleeding2.0%1.1%

CRUSADE point assignments

CRUSADE predicts in-hospital major bleeding among patients with NSTEMI. Its eight variables are hematocrit, creatinine clearance, heart rate, sex, CHF signs, vascular disease, diabetes, and systolic blood pressure. Age is not a CRUSADE variable and is not scored.

VariableCategories and points
Hematocrit<31: 9; 31 to <34: 7; 34 to <37: 3; 37 to <40: 2; ≥40: 0
Creatinine clearance≤15: 39; >15–30: 35; >30–60: 28; >60–90: 17; >90–120: 7; >120: 0
Heart rate≤70: 0; 71–80: 1; 81–90: 3; 91–100: 6; 101–110: 8; 111–120: 10; >120: 11
Female sex8
CHF signs7
Peripheral vascular disease or prior stroke6
Diabetes6
Systolic BP≤90: 10; 91–100: 8; 101–120: 5; 121–180: 1; 181–200: 3; >200: 5

CRUSADE category rates

ScoreCategoryApproximate in-hospital bleeding
≤20Very low3.1%
21–30Low5.5%
31–40Moderate8.6%
41–50High11.9%
>50Very high19.5%

Interpretation and limitations

Do not conflate the estimates. CRUSADE predicts in-hospital bleeding in NSTEMI; THEMIS-PCI reported longer-term TIMI major bleeding in stable CAD with diabetes and prior PCI. Populations, endpoints, and time horizons differ.

NNT and NNH are reciprocals of rounded absolute differences from the subgroup report. They are approximate, apply to the trial population and follow-up, and are not patient-specific predictions.

Clinical context

  • Consider prior bleeding, anemia, renal function, age and frailty, anticoagulation, ischemic risk, prior antiplatelet tolerance, and patient preferences.
  • Confirm similarity to the THEMIS-PCI population and consult current guidelines and approved product information.
  • Do not use this tool alone to decide whether to start or continue ticagrelor.

References

Bhatt DL, Steg PG, Mehta SR, et al.Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019;394:1169–1180. DOI 10.1016/S0140-6736(19)31887-2; PMID 31484629.
Subherwal S, Bach RG, Chen AY, et al.Baseline risk of major bleeding in non–ST-segment-elevation myocardial infarction: the CRUSADE Bleeding Score. Circulation. 2009;119:1873–1882. DOI 10.1161/CIRCULATIONAHA.108.828541; PMID 19332461.
Clinical disclaimer: Educational tool only. It displays a CRUSADE score and published group averages; it does not calculate individualized long-term bleeding risk, personal ischemic benefit, or net clinical benefit. It does not replace clinical judgement, guidelines, or shared decision-making.